VBL's pipeline also includes the Lecinoxoids family of anti-inflammatory small molecules. In 2016, we presented results for the Phase-2-ready VB-201 drug candidate and the next-generation molecule VB-703 for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. We are exploring strategic collaborations that will advance the clinical and business potential of the Lecinoxoids, as well as pre-clinical assets from our VTS platform.